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Abstract: Standardized extract from the leaves of the Ginkgo biloba tree, labeled EGb761, 
is one of the most popular herbal supplements. Numerous preclinical studies have shown 
the neuroprotective effects of EGb761 and support the notion that it may be effective in the 
treatment and prevention of neurodegenerative disorders such as Alzheimer’s disease 
(AD). Despite the preclinical promise, the clinical efficacy of this drug remains elusive. In 
this review, possible mechanisms underlying neuroprotective actions of EGb761 are 
described in detail, together with a brief discussion of the problem of studying this herb 
clinically to verify its efficacy in the treatment and prevention of AD. Moreover, various 
parameters e.g., the dosage and the permeability of the blood brain barrier (BBB), 
impacting the outcome of the clinical effectiveness of the extract are also discussed. 
Overall, the findings summarized in this review suggest that, a better understanding of the 
neuroprotective mechanisms of EGb761 may contribute to better understanding of the 
effectiveness and complexity of this herb and may also be helpful for design of therapeutic 
strategies in future clinical practice. Therefore, in future clinical studies, different factors 
that could interfere with the effect of EGb761 should be considered.  
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1. Introduction 
The leaves of the Ginkgo tree have a long history of being used for medicinal purposes. In the early 
1970s, Dr. Willmar Schwabe Pharmaceuticals (Karlsruhe, Germany) successfully improved 
methodical procedures for the extraction and standardization of Ginkgo biloba preparation and 
produced highly concentrated and stable extracts from Ginkgo biloba leaves [1]. The extract of Ginkgo 
biloba  leaves (EGb761) since then has been standardized to contain 24% flavonoid glycosides 
(containing quercetin, kaempferol, isorhamnetin ect.), 6% terpenoids (in which 3.1% are ginkgolides 
A, B, C, and J and 2.9% is bilobalide), and 5–10% organic acids (Figure 1). The flavonoids and 
terenoids are suggested to be the pharmacologically active constituents of EGb761 [2,3]. The organic 
acids in the extract contribute to its water solubility [4]. So far, numerous preclinical studies evaluating 
EGb761 effects have been undertaken and suggest the neuroprotective effects of this herb [5–11]. 
Nowadays, EGb761 has been widely used in the treatment and prevention of neurodegenerative 
dementias associated with ageing, Alzheimer’s Disease (AD), peripheral vascular diseases, and 
neurosensory problems (e.g., tinnitus) [8,12,13].  
Figure 1. (A) Chemical structure of some representative flavonoid-O-glycosides and   
(B) terpene trilactone constituents of EGb761. 
 
 
AD is one of the most common neurodegenerative disease associated with progressive cognitive 
and memory loss. The major molecular hallmarks of this disorder include extracellular deposition of 
the amyloid β peptide (Aβ) in senile plaques, intracellular neurofibrillary tangles, cholinergic deficit 
and neuronal loss in brain regions critical for memory and cognition [14–17]. A number of possible 
mechanisms for the pathological changes observed in AD brains include oxidative stress, inflammation, Int. J. Mol. Sci. 2010, 11                 
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excitotoxicity and neuronal apoptosis [14,18–23]. Several protective agents such as antioxidants,   
anti-inflammatory drugs, cholinergic agents, estrogens, neurotrophic factors and calcium ion channel 
antagonists have been proposed for the prevention and treatment of AD, but none of them is proved to 
have a definite therapeutic effect [14,15,24–30]. In contrast, EGb761 has long been thought to be 
“multivalent” [7] and demonstrated to possess different profiles of action of various commonly-used 
drugs proposed for AD [30]. EGb761 thus has the potential to treat or prevent AD. 
2. Mechanism of Neuroprotection by EGb761 and Its Constituents 
2.1. Antioxidant Activity 
Oxidative stress has long been thought to play a major role in the pathogenesis of AD [18]. The 
proposal that the beneficial action of EGb761 is mainly due to its free-radical scavenging action is 
supported by numerous in vitro and in vivo studies [7]. For example, pretreating cerebellar granule 
cells with EGb761 effectively attenuated oxidative damage triggered by H2O2/FeSO4 [31]. In another 
study using two AD models, Aβ-expressing neuroblastoma cell lineN2a and Aβ-expressing transgenic 
Caenorhabditis elegans, EGb761 was found to be able to attenuate the basal as well as the induced 
levels of H2O2-related reactive oxygen species (ROS) [7,32].  
In addition to direct attenuation of ROS, EGb761 may also stabilize the cellular redox state by  
up-regulation of the protein level and activity of antioxidant enzymes [5]. For example, EGb761 was 
found to be able to increase the protein level and activity of superoxide dismutase (SOD) and catalase 
in rat hippocampus and rat ileum [5,33,34]. Moreover, activity of glutathione (GSH) reductase and 
gamma-glutamylcysteinyl synthetase, two enzymes critical for reduction and synthesis of GSH, were 
also enhanced by EGb761 [5,35,36]. 
The flavonoid fraction is suggested to be mainly responsible for the antioxidant properties of 
EGb761. It is proposed that, the flavonoid fraction evokes antioxidant effects via direct scavenging 
ROS, chelating prooxidant transitional metal ions and increase in antioxidant proteins such as SOD 
and GSH [7,37–40]. The polyphenol structure of flavonoids (Figure 1A) is thought to be responsible 
for their antioxidant actions [7,41]. Quercetin [42] and myricetin, two flavonoid constituents with such 
structure, especially effectively inhibit oxidation of tert-butylhydroperoxide [5]. In contrast, the 
antioxidant activity of terpene lactones is still in dispute [5]. There are conflicting data regarding the 
superoxide scavenging activity of bilobalide and the ginkgolides B, C and J [5,43,44]. Ginkgolide A 
has been demonstrated to lack the ability to scavenge the superoxide [5]. The discrepancy on the 
antioxidant activity of the terpene lactones may be explained as being due to differences in the type of 
oxidative stress used as well as the experimental models [5]. 
2.2. Protective Effects on Mitochondrial Function 
Abnormalities in mitochondrial function are suggested to be associated with the pathological 
changes seen in AD [45]. Recently, EGb761 has been proposed to have direct protective effects on 
mitochondria. This may also contribute to its antioxidant effects, as mitochondrial respiratory chain is 
both the major target and the major source of ROS. Using SH-SY5Y cells, we reported that, EGb761 
prevented amyloid β peptide (Aβ)-induced mitochondrial dysfunction, and thus reduced intracellular Int. J. Mol. Sci. 2010, 11                 
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ROS generation [3]. This protective effect was observed with ginkgolide B but not with quercetin [3]. 
In another study using mitochondria isolated from PC12 cells, EGb761 and bilobalide up-regulated the 
gene expression of mitochondrial NADH dehydrogenase and decreased stage 4 respiration, whose 
increase is indicative of oxidative damage in mitochondria [46]. Protective effects of EGb761 on 
mitochondrial functions have also been demonstrated in in vivo studies. Using two animal models of 
aging, the senescence accelerated prone 8 mouse strain (SAMP8) and ovariectomized rats, we recently 
reported that EGb761 treatment effectively prevented the decrease of cytochrome c oxidase (COX) 
activity, mitochondrial ATP content and mitochondrial GSH content in hippocampi of aged SAMP8 
mice and ovariectomized rats [47,48]. Despite these evidences, mechanisms underlying the protective 
effects of EGb761 and its constituents on mitochondrial function are still unclear and necessitate 
further studies. 
2.3. Anti-Apoptotic Effect 
Apoptosis has been implicated in the pathogenesis of various neurodegenerative diseases like   
AD [7,23,49]. As summarized by Smith and Luo in a review, the anti-apoptotic actions of EGb761 are 
multifactorial and may act synergistically upon multiple intracellular signaling pathways involved in 
apoptosis [4,7]. As for possible mechanisms underlying its anti-apoptotic action, EGb761 may 
maintain the integrity of the mitochondrial membrane; prevent cytochrome c release from the 
mitochondria, thereby blocking the formation of the apoptosome and the apoptotic caspase cascade; 
enhance the transcription of antiapoptotic Bcl-2-like protein; attenuate the transcription of   
pro-apoptotic caspase-12; inactivate pro-apoptotic c-Jun N-terminal kinase (JNK), thereby “turning 
off” downstream target c-Jun; inhibit the cleavage of the key effector protease caspase-3, thereby 
blocking the execution of apoptosis and prevent nuclear DNA fragmentation, the molecular hallmark 
of apoptosis [3,7,50]. 
The flavonoid fraction of EGb761 may be partly responsible for its anti-apoptotic properties. 
Despite the evidence that flavonoids prevent cell apoptosis induced by various oxidants [37–41], 
beneficial effects of EGb761 may go beyond its free-radical scavenging properties. Recently, 
evidences have accumulated to show that anti-apoptotic effects of flavonoids may be associated with 
modulation of specific proteins central to intracellular apoptotic signaling cascades such as the 
mitogen-activated protein kinase (MAPK) cascade. Quercetin, one of the major flavonoid constituents 
in EGb761 for example, did not inhibit JNK activity and apoptosis induced by hydrogen peroxide and 
4-hydroxy-2-nonenal [51–53]. It is proposed that, quercetin exerts its anti-apoptotic effects by 
inactivation of the peroxide-induced JNK-c-Jun/AP-1 pathway and extracellular signal-regulated 
kinase (ERK)-c-Fos/AP-1 pathway [53,54]. But low concentrations of quercetin could also promote 
cellular survival by activation of the MAPK pathway (ERK2, JNK1, and p38), leading to expression of 
downstream survival genes (c-Fos, c-Jun) and defensive genes (phase II detoxifying enzymes;   
GSH S-transferase, quinone reductase) [55].  
The terpene fraction of EGb761 may also contribute to its anti-apoptotic properties. Bilobalide, 
ginkgolide B, and ginkgolide J were demonstrated to be able to attenuate apoptosis in chick embryonic 
neurons caused by 24-h exposure to serum deprivation [56,57]. Bilobalide could also reverse apoptotic 
damage induced by 12-h staurosporine treatment of chick neurons [57]. In mixed cultures of neurons Int. J. Mol. Sci. 2010, 11                 
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and astrocytes from neonatal rat hippocampus, bilobalide rescued the neurons from serum deprivation-
induced apoptosis, and both bilobalide and ginkgolide B attenuated staurosporine-triggered apoptotic 
damage [57]. However, ginkgolide A failed to block apoptotic damage either in serum-deprived or in 
staurosporine-treated neurons [58]. Analysis of DNA fragmentation and the activities of   
caspase-1- and caspase-3- like protease suggest that bilobalide can block neuronal apoptosis in the 
early stage by attenuating the elevations of c-myc, p53, and Bax and the activation of caspase-3 [57]. 
Similarly, the anti-apoptotic effects of ginkgolides are also suggested to be associated with blockage of 
early signaling events in apoptosis. A recent study demonstrated that ginkgolide B inhibited ethanol-
induced apoptotic cell death via suppression of activation of JNK and caspase 3 [59]. Our recent study 
supported this finding by showing that ginkgolide B protected against Aβ-induced activation of JNK, 
ERK1/2 and Akt signaling pathways and DNA fragmentation in SH-SY5Y cells [3]. However, there 
are also contrasting data showing that the terpene constituents of EGb761 have no protective effect on 
cell apoptosis. For example, bilobalide failed to protect primary adult rat hippocampal neurons against 
apoptosis caused by a peroxyl radical-generator, 2,2′-azobis-2-amidinopropane [57,60]. In another 
study, the terpenes of EGb761 could not block hydroxyl radical-induced apoptosis in rat cerebellar 
granule cells [61]. This discrepancy may be due to the different types of cells and different methods for 
inducing apoptosis [57]. 
Despite the anti-apoptotic effects of EGb761 and its pharmacologically active components, the pro-
apoptotic action of EGb761 and its constituents (e.g., quercetin and ginkgolide B) has also been 
demonstrated [50]. Treatment dosage may be one of the vital factors that determine the specific action 
of EGb761 and its constituents on apoptosis [50] (discussed below). 
2.4. Anti-Inflammatory Effect 
Inflammation has been implicated in the pathology of AD [62]. Cytokines, acute phase reactants, 
and other inflammatory mediators have been found to be up-regulated in pathologically vulnerable 
regions of AD brains [62]. EGb761 has been demonstrated to have anti-inflammatory effects [63–65]. 
These effects may be attributed to the combined actions of its ginkgolide and flavonoid constituents [65].  
The anti-inflammatory action of ginkgolides may be associated with their platelet-activating factor 
(PAF) -antagonist activity. Substantial evidence suggests the role of PAF as a regulator of cytokines in 
inflammatory responses [4,66]. Intracerebroventrical administration of PAF in rats could stimulate the 
synthesis of pro-inflammatory mediator leukotriene, particularly leukotriene C4 [4,67]. PAF can be 
synthesized in neurons following stimulation with neurotransmitters such as N-methyl-D-aspartic acid 
(NMDA) and glutamic acid and plays various roles in neuronal functions and brain development [68]. 
However, increased concentrations of PAF in the brain are also implicated in neurodegenerative 
diseases such as AD [69,70]. Ginkgolides display very specific and potent antagonist effects against 
PAF [65]. Intracerebroventrical administration BN-52021 (ginkgolide B) in rats significantly 
attenuated PAF-induced rise in cerebrospinal fluid peptidoleukotriene levels [4,67]. BN-52021 could 
also reduce PAF-induced production of the eicosanoid and thromboxane B in a fetal rat brain [4,71]. In 
support of these findings, our recent study has shown that ginkgolide B could completely block   
PAF-induced decrease of cell viability in SH-SY5Y cells [3]. In addition to PAF-antagonizing activity, 
the inhibitory effects of ginkgolides A and B on pro-inflammatory cytokines tumour necrosis   Int. J. Mol. Sci. 2010, 11                 
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factor-alpha and interleukin-1 production in lipopolysaccharide-stimulated rat microglial cultures were 
also observed [4,72]. 
On the other hand, the flavonoid fraction of EGb761 reportedly inhibits lipooxygenase that is 
concerned with the formation of leukotrienes [65]. In addition, in one of our recent studies, we have 
demonstrated that, a flavonoid constituent of EGb761, quercetin may also be involved in EGb761’s 
PAF-antagonist activity [3]. 
2.5. Protective Effects against Amyloidogenesis and Aβ Aggregation 
The accumulation of Aβ plaques has been proposed to be one of the most prominent mechanisms 
underlying the pathology of AD [73]. Recently, the role of EGb761 in the protection against the  
Aβ-induced toxicity has received much attention. A number of recent reports indicate that EGb761 
protects against Aβ-induced neurotoxicity by blockage of Aβ-induced events, such as ROS 
accumulation, glucose uptake, mitochondrial dysfunction, activation of AKT, JNK and ERK 1/2 
pathways and apoptosis [3,74,75]. In addition to the protective effects against Aβ, EGb761 has also 
been shown to prevent amyloidogenesis [76–79]. On hippocampal slices, Colciaghi et al. demonstrated 
that EGb761 could push amyloid precursor protein (APP) metabolism towards the α-secretase 
pathway, thereby increasing the release of the soluble form of APP (sAPPα) [76,78]. Using the 
transgenic AD model Tg2576 mice, the consequence of the capability of EGb761 to influence 
positively the α-secretase pathway was also assessed in vivo. [78,79]. It was found that, after EGb761 
treatment, Tg-2576 mice exhibited an enhancement of spatial learning and memory comparable to wild 
type mice [78,79]. It has been proposed that, EGb761 inhibits the production of brain Aβ by lowering 
the levels of circulating free cholesterol, as free circulating and intracellular cholesterol levels could 
affect APP processing and amyloidogenesis [77,78,80–82]. Despite these evidences, further 
investigations are needed to identify the major constituents responsible for this antiamyloidogenic effect. 
EGb761 could also inhibit the formation of Aβ fibrils [78,86]. It is known that, the β-sheet structure 
of Aβ fibrils is mainly responsible for the neurotoxicity of Aβ and may also help Aβ escape from 
clearance via proteolytic degradation [78,83–85]. Thus, inhibiting of formation of β-sheet structure of 
Aβ fibrils may also help to prevent Aβ toxicity. The interaction of Aβ with transition metal ions, 
notably iron, zinc and copper, could influence the aggregation state of Aβ. EGb761, through its iron 
chelating property, may inhibit Aβ fibrils formation [78,86]. EGb761 may also influence the formation 
of Aβ fibrils by increasing gene expression of transthyretin [87], as transthyretin has been shown to 
prevent Aβ aggregation in vitro by sequestering Aβ monomers [88]. The inhibitory effect of EGb761 
on Aβ aggregation was also observed with bilobalide, ginkgolide J and flavonoid compounds [78,86]. 
2.6. Other Mechanisms 
Other mechanisms which may be involved in neuroprotective effects of EGb761 on AD are ion 
homeostasis, modulation of phosphorylation of tau protein, and induction of growth factor synthesis.  
Ca
2+ dyshomeostasis may be of pivotal importance in mediating neutotoxicity in AD [89,90]. Our 
unpublished data suggested that, EGb761 could protect against Aβ (1–42)-triggered Ca
2+ influx via  
N-methyl-D-aspartic acid receptors. This effect was also observed with its constituents quercetin and 
ginkgolide B. Int. J. Mol. Sci. 2010, 11                 
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In AD brain, hyperphosphorylated microtubule-associated protein tau is aggregated as neuro-
fibrillary tangles of paired helical filaments, which is a key event in the pathogenesis of   
AD [5,91]. Using mRNA microarrays, Watanabe et al. found that EGb761 was able to up-regulate 
gene expression of microtubuli-associated tau protein as well as of neural protein phosphatase type 1, a 
serine/threonine protein phosphatase known to dephosphorylate hyperphosphorylated tau protein, in 
the hippocampus and cortex of normal mice [5,87].  
Altered levels of nerve growth factor (NGF) have been detected in AD brains [92–94]. EGb761 was 
reported to be able to up-regulated mRNA expression of NGF such as growth hormone and prolactin 
in mouse cortex [5,94]. Furthermore, the mRNA and protein expression of glial-derived neurotrophic 
factor and vascular endothelial growth factor in cultured rat cortical astrocytes could also be up-
regulated by a terpenoid constituent of EGb761, bilobalide [5,95]. 
3. Current Status of Clinical Use of EGb761: Still a Long Way from Preclinical Promise 
Despite the substantial body of preclinical evidence suggesting that EGb761 may be effective in 
treatment and prevention of AD, its clinical effect remains elusive. A recent meta-analysis of clinical 
studies (925 AD patients in 9 trials) on the use of EGb761 suggested that beneficial effects of EGb761 
in AD are inconsistent [96]. In addition, the Ginkgo Evaluation of Memory (GEM) study, the largest 
and longest randomized controlled trial of Ginkgo biloba extract concluded that EGb761 supplement 
was not effective in reducing either the overall incidence rate of dementia or AD incidence in elderly 
individuals with normal cognition or those with mild cognitive impairment [97]. These reports suggest 
to us that, despite the preclinical promise that EGb761 may be effective in treatment and prevention of 
AD, this promise has not completely translated to clinical research benefits. 
Certain confounding factors, as previously suggested [1], may be interfere with EGb761’s effect, 
and may be the source of the variations observed among EGb761 studies. First, the therapeutic effect 
of EGb761 may depend on the sensitivity of the study population to this drug. Thus the homogeneity 
of the study population may affect EGb761’s efficacy [1]. In two multicenter trials, EGb761 treatment 
showed a greater effect on the AD subgroup than the total mixed dementia population (AD and Multi-
Infarct Dementia) [1]. Moreover, it is still unclear whether age and sex influence population sensitivity 
to EGb761 treatment. Second, the therapeutic effect of EGb761 in AD may be associated with the 
severity of the impairment [1]. In the group of patients with very mild to mild cognitive impairment, 
EGb761 effect could be considered in the term of improvement while in more severe dementia, 
EGb761 effect should be considered more in terms of stabilization or slowing down of   
worsening [1,80]. Third, the sensitivity of different cognitive outcome measurements such as the 
Syndrom-Kurztest and the Alzheimer's Disease Assessment Scale-Cognitive Subscale may affect the 
assessment of EGb761’s effect, but this factor may be directly dependent on the severity of the 
cognitive impairment of the tested patients [1]. Last but not least, there may be a dose-dependent effect 
of EGb761. Nowadays, a daily dose of 240 mg has been extensively used to stabilize the disease 
progression in patients with AD [40,77,98,99]. But whether doses higher than 240 mg/day further 
enhances the effect of EGb761 remains unclear [1].  
Regarding these factors, basic researches gives useful information that may be helpful for 
modifying the clinical efficacy of EGb761. In one of our recent studies, we investigated the dosage Int. J. Mol. Sci. 2010, 11                 
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effects of EGb761 on H2O2-induced apoptosis in human neuroblastoma SH-SY5Y cells [50]. We 
found that, low doses of EGb761 (50–100 μg/mL) inhibited H2O2-induced cell apoptosis via 
inactivation of Akt, JNK and caspase 3 while high doses of EGb761 (250–500 μg/mL) enhanced H2O2 
toxicities via inactivation of Akt and enhancement of activation of JNK and caspase 3 [50]. We also 
found that, H2O2 decreased intracellular GSH content, which was also inhibited by low concentrations 
of EGb761 but enhanced after high concentrations of EGb761 treatment [50]. These results suggest 
that, EGb761 has dosage-dependent effects on H2O2-induced cell apoptosis, which may be correlated 
with regulation of cell redox state. In support of these findings, previous studies have demonstrated 
similar dosage effects of quercetin and ginkgolide B, two major components of EGb761 [53,59]. In 
addition, most of protective effects of EGb761 observed in vitro were reported at lower concentrations 
(≤200  μg/mL) [31,36,46,56,61,74,77,86,100]. Therefore, only within a certain range of dosage, 
EGb761 shows protective effects.  
EGb761 consists of hundreds of chemical constituents [77]. As ginkgolide constituents of EGb761 
represent approximately 2–3%, these compounds were recently used to monitor its bioavailability in 
vivo [77,101]. In one of our recent studies, we have demonstrated that, EGb761 at 100 μg/mL could 
protect against cell death induced by a wide range of H2O2 doses (250–1,000 μM) [50]. Similar doses 
have been reported in in vivo studies. It has been demonstrated that, after oral administration of   
240 mg/day of EGb761 to human subjects or 100 mg/kg EGb761 in rats, the concentration of 
ginkgolides in the blood reached 2–3 μg/mL, a concentration suggesting the presence of 100 μg/mL 
EGb761 in the blood [77,102]. However, even if protective concentrations of EGb761 are achieved in 
the blood, for the pharmacologically active components of EGb761 to modulate central mechanisms, 
they have to cross the BBB and accumulate in the brain. It is known that, under normal physiological 
conditions, the BBB controls tightly the entry of drugs into the central nervous system. But disruption 
of BBB is now increasingly documented in both normal ageing and neurodegenerative disorders such 
as AD [103,104]. It has been purported that, under pathological conditions such as AD, EGb761 was 
able to cross the BBB effectively and retain its neuroprotective properties [105,106], but there is a lack 
of evidence for the ability of EGb761 to cross the BBB under normal physiological conditions. Thus 
BBB permeability may be an important factor that interferes with the in vivo effects of EGb761 and 
even determines population differences in sensitivity to EGb761 treatment. In order to better 
understand the in vivo pharmacological actions of EGb761, we have used some animal models of 
aging (e.g., SAMP8 mice and ovariectomized rats) to test and compare effects of EGb761 on 
mitochondrial function in platelets and central nervous system. The rationale of employing platelet as a 
peripheral biomarker for mitochondrial damages rests on the assumption that alterations occurring in 
ageing and age-associated disorders may be present in all cells, and that changes occurring in platelet 
mitochondria may represent generalized bioenergetic deficiencies [107].  
Epidemiological studies have shown that the incidence of female AD increases significantly after 
menopause by two to three times that of males, suggesting that estrogen withdrawal may play a 
primary role in the pathogenesis of AD in post-menopausal women [14,108]. Using ovariectomized 
middle-aged rats to mimic the post-menopausal pathophysiological changes in women, we 
demonstrated that, oral administration of 100 mg/kg EGb761 protected against the decrease of COX 
activity, mitochondrial ATP content and mitochondrial GSH content in both platelets and hippocampi, 
suggesting its peripheral and central effects against estrogen withdrawal-induced degeneration [47]. In Int. J. Mol. Sci. 2010, 11                 
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contrast, in sham-operated rats, EGb761 increased mitochondrial GSH content in platelets but failed to 
show similar effect on hippocampi, indicating that EGb761 may help to enhance the functional reserve 
of mitochondria, but this effect was limited to the outside of the central nervous system [47]. Previous 
studies have demonstrated that estrogen withdrawal through ovariectomy increases the selective 
permeability of the BBB [109,110]. EGb761 displayed similar effects on platelets and hippocampi of 
ovariectomized rats but showed differential effects on platelets and hippocampi of sham-operated rats, 
possibly because estrogen withdrawal induced an increase of BBB permeability [47]. In another study 
using two age groups (3-week-old and 40-week-old) of SAMP8 mice, a model of age-related cognitive 
decline with relevance to genetic alterations and protein abnormalities in AD, we found that, oral 
administration of 100 mg/kg EGb761 protected against the decrease of COX activity, mitochondrial 
ATP content and mitochondrial GSH content in platelets of young and old mice, suggesting the 
peripheral effect of this herb in the prevention and treatment of age-associated degeneration [48]. In 
contrast, in hippocampi, protective effects of EGb761 were observed only in the old mice, probably 
due to an age-associated increase in the permeability of the BBB [48]. From these data, we speculate 
that, EGb761’s effect may be limited to the outside of the central nervous system under normal 
physiological conditions, but increased BBB permeability may enhance the central effect of EGb761. 
If so, future studies are needed to determine the ability of pharmacologically active components of 
EGb761 to cross the BBB and various methods that help to deliver them across the intact BBB may 
contribute to enhancement of EGb761’s efficacy in the prevention of AD. 
In addition, improvement of neuronal survival environment may also help to enhance neuronal 
sensitivity to EGb761. In fact, a number of aging-related neurotoxic events, such as oxidative stress 
and decreased neuronal trophic support by neurotrophic factors may co-exist to perturb neuronal 
physiological homeostasis in vivo during ageing of the central nervous system or the development of 
age-related neurodegenerative diseases such as AD [93,100]. Thus, interventions could be targeted 
accordingly or comprehensively [100]. In one of our recent studies, rat pheochromocytoma (PC12) 
cells were treated with H2O2 for 24 h to reduce intracellular GSH content to about 50% [100]. After 
withdrawal of H2O2, we determined effects of EGb761 on cell death under three different conditions of 
serum supply: normal growth medium, serum deprivation and serum deprivation followed by   
re-supply [100]. We found that, under the condition of serum deprivation, the percentage of dead cells 
is lower than under the condition of serum supply, partially via inhibition of mitochondrial   
metabolism [100]. Moreover, after serum deprivation, serums re-supply exacerbated cell necrosis, 
possibly through enhancement of oxidative damage [100]. EGb761 protected against cell death under 
the condition of serum supply whereas showed little protective effects on serum-depleted cells [100]. 
These results suggest that, there may be a synergistic effect between trophic factors and EGb761 [100]. 
EGb761 prevents cells from possible oxidative damage induced by the trophic factors [100]. On the 
other hand, trophic factors strengthen cellular responses to EGb761 treatment [100]. Therefore,   
a combined treatment of EGb761 and neurotrophic factors in future basic and clinical research   
is proposed. 
Overall, these findings suggest that, to achieve a stable and satisfied clinical efficacy of EGb761, 
different factors that could interfere with the efficacy of this drug should be considered.  
Despite our data suggesting that high doses of EGb761 may exacerbate cellular oxidative damage 
and apoptosis, no serious side effects of EGb761 have been noted in any trials so far [5]. Only mild Int. J. Mol. Sci. 2010, 11                 
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gastrointestinal complaints, dizziness, headache, dry mouth, sleep disturbances, transient cyanosis of 
nails and lips, and allergic skin reactions have been reported in rare cases [5]. Moderate concentrations 
of EGb761 seem to be well tolerated [5]. 
4. Conclusions 
Various in vivo and in vitro preclinical studies support the notion that standardized Ginkgo biloba 
extract EGb761 may be effective in the treatment and prevention of AD and other age-related, 
neurodegenerative disorders. Anti-oxidation, anti-apoptosis, anti-inflammation, protection against 
mitochondrial dysfunction, amyloidogenesis and Aβ aggregation, ion homeostasis, modulation of 
phosphorylation of tau protein and even induction of growth factors are possible mechanisms of 
action. However, the clinical efficacy of EGb761 still remains elusive. Multiple factors such as 
population sensitivity, severity of impairment, type of assessments used to measure efficacy and doses 
were suggested to be able to interfere with EGb761 efficacy in clinical practice. Regarding these 
factors, basic scientific reports give useful information that may help to modify the clinical efficacy of 
this drug. Overall, a better understanding of the mechanisms underlying neuroprotective effects of 
EGb761 may contribute to better understanding of the effectiveness and complexity of this drug, and 
may also be helpful for designing therapeutic strategies in future clinical practice. 
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